Sol-Gel Technologies
Update in progressSLGL (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Sol-Gel Technologies Ltd., with its subsidiary Sol-Gel Technologies Inc., develops topical dermatology drugs for severe skin conditions in Israel, China, Switzerland, Canada, the United States and beyond. It markets Twyneo for acne vulgaris and Epsolay for papulopustular rosacea. It is advancing SGT-610 in Phase 3 for Gorlin syndrome and SGT-210 in Phase 1 for Olmsted syndrome. It collaborates with Padagis Israel, and licenses with Galderma and Searchlight. Founded 1997, headquartered in Ness Ziona, Israel.
Company score
- Sentiment
- -0.16
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.19
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.04
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!